Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma

 
• By Ian Schofield

Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.

Lung radiography
An orphan drug for mesothelioma is one of two products withdrawn from the CHMPassessment process

More from Product Reviews

More from Pink Sheet